How a Drug Company Made $114 Billion by Gaming the U.S. Patent System


AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end.

Previous Story

Sam Bankman-Fried’s Prosecutors Ask Judge to Tighten Bail Conditions

Next Story

Johnson & Johnson’s Talc-Related Bankruptcy Filing Is Rejected